Dr. Edlira Tam

Mom/Wife. Advanced Heart Failure & Transplant Cardiologist🫀Tweets are my own!

[Stony Brook Department of Medicine @sbudeptofmed]

The @sbudeptofmed is pleased to announce the promotion of Edlira Tam, DO, MS, FACC, Division of Cardiology @StonyBrookMed to Clinical Associate Professor of Medicine in the Renaissance School of Medicine @stonybrooku https://t.co/ie3iwoMWYJ 👏

[Brett Sperry, MD @BrettSperryMD]

Congratulations @DorbalaSharmila for leading this study and kicking it off with the first patient enrolled!

[Aakash Tuli @AakashTuliMD]

1️⃣4️⃣ Pro Tip:
For more details, review the ATS/ACCP Statement on Cardiopulmonary Exercise Testing! 📚

Source (Excellent read): https://t.co/KJkSi3Yjrj
@ACCinTouch #Cardiology #CPET #MedEd 💡

[C. Michael Gibson MD @CMichaelGibson]

Tirzepatide (Mounjaro®) successful in SUMMIT phase 3 study showing benefit in adults with HFpEF and obesity, 38% reduction of HF hospitalization, diuretic intensification, or CV death. Dr. Packer shares results of SUMMIT trial
https://t.co/3Ur7olrY3j

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

#LBCT #SUMMIT trial #AHA24
💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity
📎 @NEJM

[NEJM @NEJM]

Presented at #AHA24:

In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo. Full trial results: https://t.co/ib0n1GaRtR

[Gregg Fonarow MD @gcfmd]

The use of SGLT2i is associated with a significant reduction in the risk of all-cause mortality, major adverse CV events (composite of AMI, ischemic stroke, hemorrhagic stroke, and cardiac arrest), and ischemic stroke in patients with ATTR-CM

[Dr. Edlira Tam @EdliraTam]

@DrTGupta @ACCinTouch @JACCJournals @KendraGrubb @ChrisMalaisrie @_WayneBatchelor @KDBoudoulas @MReardon19 Congratulations 🎊🍾

[JACC Journals @JACCJournals]

Critical care cardiology is a robust and growing subspecialty. Take a closer look at this #JACC expert consensus on best practices for setting up a quality critical care cardiology program: https://t.co/hm35Dv7457

#ACCCriticalCare #ACCFIT @criticalecho @AndreaElliottUM @JasonKatzMD @criticalecho @SarasVallabhMD @ddbergMD @RanLeeMD @UMN_CCCEdSummit @MGHHeartHealth @ACCinTouch

[Dr. Edlira Tam @EdliraTam]

@RyanTedfordMD @ISHLT Very important discussion. Have seen this a few times in our patients thus far. Looking forward to this webinar.

[Dr. Edlira Tam @EdliraTam]

We are raising money for children with disabilities and their families so they can get the school resources and programs they need. If you can, please help my 4 year old son with this cause. Thank you!
https://t.co/jGYBsqDjc2

[The ISHLT @ISHLT]

📢 A NEW #ISHLTConsensusStatement on Strategies to Prevent and Manage #Hemocompatibility Related Adverse Events in Patients with Durable #VADs is now available online at https://t.co/2WtI0wnjZV.

Check out the top takeaways from this document below. ⏬🫀💡 #HF #TxPharm #LVAD

[Dr. Edlira Tam @EdliraTam]

Are GLP1-i the 5th Pillar for HFrEF GDMT? A phenomenal talk by Dr. Yancy at the Monteheart Symposium. “We have to persist with discovery and establish the 5th Pillar” @NMHheartdoc @MonteHeart @UlrichJordeMD

[Dr. Edlira Tam @EdliraTam]

Excited to be back where it all began. I learned everything I know in Cardiology and HF from these outstanding leaders in the field. So many emotions walking down these hallways. @MonteHeart

[Ahmad Masri @MasriAhmadMD]

The #SEQUOIA #HCM trial results are here - Placebo-controlled trial of #aficamten in #obstructive #HCM

3 presentations in 3 threads - follow along

This is the first presentation by @MartinMaronMD sharing the primary results
Follow along #CardioTwitter #HeartFailure2024

[AHA Science @AHAScience]

Hypertrophic Cardiomyopathy (HCM) remains a common genetic heart disease in populations throughout the world.

The 2024 Guideline for the Management of Hypertrophic Cardiomyopathy was published today in @CircAHA.

✍🏼 @SteveOmmen

📷 Recommended Evaluation & Testing for HCM

[Eric Topol @EricTopol]

Gliobastomas are among the most aggressive and fatal cancers. After marked success treating 10 dogs, a unique IV "onionized" mRNA/nanoparticle individualized vaccine induced a striking anti-tumor immune response
https://t.co/36OBimFOAB @CellCellPress @UF

[Dr. Edlira Tam @EdliraTam]

@CardioMDPhD @ASPCardio @MonteHeart @DrMichaelShapir @virani_md @damini_dey @danielbermanmd @RonBlankstein @lesleejshaw Congratulations 🎊 well deserved

[Ahmad Masri @MasriAhmadMD]

An effect size that is unlikely to ever be reproduced